The Global Continuous Renal Replacement Therapy Market is projected to grow at a CAGR of 7.7% between 2021 and 2027, with a market worth of US$ 1 billion in 2021 expected to reach US$ 1.68 billion in 2027. This therapy involves the removal of solutes from the blood through hemofiltration or hemodialysis or a combination of both for approximately 24 hours in an ICU, unlike traditional renal replacement therapies such as IHD that last 4-6 hours.
The industry leaders are adopting technological advancements for acute therapy. In 2019, Baxter International Inc. received clearance for its integrated TherMax blood warmer and PrisMax system for TPE and continuous renal replacement therapy. Software integration is being explored as a novel tool for efficient and safe continuous renal replacement therapies. Baxter’s PRISMAFLEX system and B. Braun’s Diapact Continuous Renal Replacement Therapy (CRRT) are flexible platforms that offer personalized therapies.
Request Sample Copy of Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-1211
However, the lack of uniform regulations across different governments could hinder market growth. For example, the US FDA prohibits the use of CRRT to treat multiple symptoms related to kidney, heart, or liver-related diseases. In contrast, CRRT is approved for liver support, cardiac failure, elevated Intercranial Pressure, intoxication, post-cardiac surgery, and rhabdomyolysis in Europe. These factors may limit market expansion. The latest market study from Future Market Insights, titled “Continuous Renal Replacement Therapy market,” provides insights into these issues.
Key Takeaways from Continuous Renal Replacement Therapy market
- North America holds more than 30% of the market share due to exploding geriatric population that is at the risk of kidney disorders. This holds true with the fact that the US Department of Health and Human Services has stated that around 37 Mn people all across the US are suffering from CKD (Chronic Kidney Disease).
- Europe comes in second on the similar grounds.
- Coming to the Asia-Pacific, increase in occurrences of chronic kidney diseases, hypertension, and diabetes is likely to create creative disruption in the Continuous Renal Replacement Therapy market. It needs to be noted that the government of China, in March 2019, reduced VAT (Value Added Tax) to 13% (from 13.3%).
Avail Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-1211
Key Players:
Some of the key players featured in the report include Fresenius Medical Care AG & Co. KGaA; Baxter International Inc.; B. Braun Melsungen AG; Medica SpA; Nikkiso Co., Ltd.; Nipro corp.; Toray Medical Co., Ltd.; NxStage Medical, Inc.; Asahi Kasei Corp. and Medtronic plc.
Competitive Analysis
- DaVita, in February 2021, encompassed DaVita Care Connect (a secure healthcare platform) into the home dialysis program.
- Medtronic plc, in December 2020, did announce launching Carpediem Cardio-Renal Pediatric Dialysis Emergency Machine. The major objective was to have it utilized in the ones who require hemodialysis.
- Fresenius Medical Care, in April 2020, announced releasing an advisory stating that the ones needing renal replacement therapy in the pandemic era could be proffered with it even now on directions of physicians.
- Baxter International Inc., in April 2020, announced that it enhanced the supply of the critically required products all across.
- B. Braun Avitum AG, in March 2021, announced signing a co-marketing contract with its OMNIset Plus bloodline set version 3.0 or even higher with continuous purification of blood (OMNI) platform for using CytoSorb.
- Fresenius Medical Care, in June 2021, did inaugurate training center in South Korea, so as to extend support to education for the healthcare personnel in renal care, critical care, and treatment surgeries.
“With growing incidences of AKI (Acute Kidney Injury), sepsis, and likewise, the number of urgent care centers and hospitals are rising limitlessly. This factor is bound to take the Continuous Renal Replacement Therapy market by storm in the forecast period”, says an analyst from Future Market Insights.
What does the Report Cover?
- The research study is based on product type (dialysis system and consumables (hemofilter sets, solution, and accessories), and by end-user (dialysis center and hospital).
- With sepsis and various other biomarkers being introduced for identifying multiorgan failure, that too, at initial stages, the global Continuous Renal Replacement Therapy market is bound to reach greater strides in the upcoming period.
Customization Available@ https://www.futuremarketinsights.com/customization-available/rep-gb-1211
Segmentation:
The research provides a detailed taxonomy of the global continuous renal replacement therapy market by product type, end user, and geography. There are two types of continuous renal replacement therapy: systems and consumables. The consumables category includes a variety of hemofilter sets, solutions, and other accessories.
Increasing healthcare spending in emerging nations is predicted to foster the formation of new multi-specialties in dialysis centres and hospitals, hence increasing demand for CRRT. The market for continuous renal replacement treatment has been studied in several regions, including North America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding Japan, Japan, and the Middle East and Africa.
About FMI:
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs
